Although alirocumab and evolocumab have both been associated with improved outcomes in patients with dyslipidemia or established atherosclerotic cardiovascular disease, data on their respective performances are scarce. This study aimed at providing an indirect comparison of the efficacy and safety of alirocumab versus evolocumab.
Indirect Comparison of the Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Network Meta-Analysis
Indolfi, Ciro;
2020-01-01
Abstract
Although alirocumab and evolocumab have both been associated with improved outcomes in patients with dyslipidemia or established atherosclerotic cardiovascular disease, data on their respective performances are scarce. This study aimed at providing an indirect comparison of the efficacy and safety of alirocumab versus evolocumab.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
